Lant Medical has developed HELIX; a treatment for _Helicobacter Pylori (H. pylori_). 50% of the global population are infected with this bacteria; it causes gastritis, peptic ulcers and is found in 95% of gastric cancer patients. Lant Medical plan to take existing HELIX prototypes, and companion diagnostic into manufacture to GMP and MHRA regulations and design a clinical trial. HELIX is a novel innovative treatment for H. Pylori infections that could disrupt the existing pathway. Dramatically, reducing costs to the NHS, improving patient outcomes with early detection for gastric cancer, and facilitating an easy form of self-care improving a patients journey from diagnosis to treatment. Lant Medical will establish our first route to market as a 'Special' for anyone suffering from an allergy or resistance to antibiotics. A well experienced network of NIHR departments and NHS trusts are supporting the development of Lant Medical, from prototypes through the regulatory process & validation into the drug development and clinical trial preparation. This project will allow Lant Medical to transition smoothly into Phase 3 clinical trial to achieve a fully licenced new cost effective more natural solution to an _H. pylori_ infection which infects over 50% of the global population. Saving antibiotic use for when they are really needed. Project Outcomes include: 1) Manufactured 'Biologic' to GMP & MHRA standards 2) Design a clinical trial 3) International PCT patent rollout for highly infected countries 4) Working with a North East University to use their educational and information tool to disseminate the availability and use of HELIX to NHS Trusts and GP practices; encouraging adoption.